Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer: A Multicenter, Prospective, Randomized Controlled Study

NCT07730151 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT07730151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07730151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer: A Multicenter, Prospective, Randomized Controlled Study
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
December 31, 2031
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate, prostate cancer, prostate cancer patients